content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001767215</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001100682</issuerCik>
        <issuerName>Charles River Laboratories</issuerName>
        <secFileNumber>001-15943</secFileNumber>
        <issuerAddress>
          <com:street1>251 Ballardvale Street</com:street1>
          <com:city>Wilmington</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>01887</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>781-222-6600</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Joseph LaPlume</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Officer</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>UBS Financial Services Inc</name>
          <address>
            <com:street1>1000 Harbor Blvd</com:street1>
            <com:street2>3rd Floor</com:street2>
            <com:city>Weehawken</com:city>
            <com:stateOrCountry>NJ</com:stateOrCountry>
            <com:zipCode>07086</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>959</noOfUnitsSold>
        <aggregateMarketValue>185087</aggregateMarketValue>
        <noOfUnitsOutstanding>51180000</noOfUnitsOutstanding>
        <approxSaleDate>05/12/2023</approxSaleDate>
        <securitiesExchangeName>NYSE</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <acquiredDate>02/23/2018</acquiredDate>
        <natureOfAcquisitionTransaction>Performance Stock Award</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Charles River Laboratories</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>959</amountOfSecuritiesAcquired>
        <paymentDate>02/23/2018</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <noticeSignature>
        <noticeDate>05/12/2023</noticeDate>
        <signature>/s/ UBS Financial Services Inc, as attorney-in-fact for Joseph LaPlume</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2829}]
text: 144
  0001767215
  XXXXXXXX
  LIVE
  0001100682
  Charles River Laboratories
  001-15943
  251 Ballardvale Street
  Wilmington
  MA
  01887
  781-222-6600
  Joseph LaPlume
  Officer
  Common
  UBS Financial Services Inc
  1000 Harbor Blvd
  3rd Floor
  Weehawken
  NJ
  07086
  959
  185087
  51180000
  05/12/2023
  NYSE
  Common
  02/23/2018
  Performance Stock Award
  Charles River Laboratories
  N
  959
  02/23/2018
  Cash
  Y
  05/12/2023
  /s/ UBS Financial Services Inc, as attorney-in-fact for Joseph LaPlume